Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Increased by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC raised its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 1.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,244,450 shares of the company’s stock after buying an additional 17,723 shares during the period. ArrowMark Colorado Holdings LLC owned about 1.81% of Arvinas worth $30,651,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its stake in shares of Arvinas by 55.1% during the 1st quarter. Janus Henderson Group PLC now owns 32,429 shares of the company’s stock worth $1,337,000 after acquiring an additional 11,520 shares in the last quarter. California State Teachers Retirement System lifted its stake in Arvinas by 17.5% during the first quarter. California State Teachers Retirement System now owns 57,059 shares of the company’s stock valued at $2,355,000 after buying an additional 8,497 shares in the last quarter. Contravisory Investment Management Inc. purchased a new position in shares of Arvinas in the second quarter worth approximately $185,000. SG Americas Securities LLC raised its holdings in shares of Arvinas by 137.2% during the second quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock valued at $2,292,000 after acquiring an additional 49,799 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Arvinas by 6.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 65,907 shares of the company’s stock valued at $1,754,000 after acquiring an additional 4,045 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Trading Up 2.8 %

Arvinas stock opened at $26.72 on Monday. The company has a market capitalization of $1.84 billion, a P/E ratio of -5.72 and a beta of 1.96. Arvinas, Inc. has a 1-year low of $21.17 and a 1-year high of $53.08. The firm’s fifty day simple moving average is $25.68 and its 200-day simple moving average is $26.70.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.20. The company had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. During the same quarter last year, the business earned ($1.18) EPS. The company’s revenue for the quarter was up 196.0% on a year-over-year basis. On average, equities research analysts predict that Arvinas, Inc. will post -3.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Stephens started coverage on shares of Arvinas in a research note on Monday, November 18th. They set an “overweight” rating and a $55.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th. BMO Capital Markets reduced their price objective on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research note on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and set a $87.00 target price on shares of Arvinas in a research note on Thursday, October 31st. Finally, Oppenheimer reduced their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.08.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.